

**Question for written answer E-003898/2025**

**to the Commission**

Rule 144

**Valérie Deloge (PfE), Ondřej Knotek (PfE), Mélanie Disdier (PfE), Pierre Pimpie (PfE), Volker Schnurrbusch (ESN), Céline Imart (PPE), Marie-Luce Brasier-Clain (PfE)**

**Subject:** Approval of effective vaccines against lumpy skin disease without undermining agricultural exports

Lumpy skin disease (LSD) is a major health threat to French and European cattle herds, and vaccination is the main tool for prevention.

A number of farmers and professional organisations have highlighted the existence of vaccines developed outside the EU, such as India, which are considered more effective than those currently available in the EU. Unlike the vaccines used to date, they make it possible to distinguish vaccinated animals from infected animals and thus put paid to any risk of exports being blocked.

However, owing to approval and mutual recognition procedures, they are not available on the European market. As a result, French farmers are being deprived of a solution that is potentially more protective and better suited to maintaining their international competitiveness.

1. With a view to their swift approval in the EU, does the Commission intend to assess the safety and effectiveness of those vaccines?
2. What guarantees can it provide French farmers that the LSD vaccination strategy will not undermine their exports?

Supporters<sup>1</sup>

Submitted: 3.10.2025

---

<sup>1</sup> This question is supported by Members other than the authors: Jean-Paul Garraud (PfE), Julien Leonardelli (PfE)